Skip to main content

Advertisement

Table 4 Comparison of observed clinical outcomes: IMRT-SIB cohort and published 3DCRT cohort[15]

From: Adjuvant concurrent chemoradiation using intensity-modulated radiotherapy and simultaneous integrated boost for resected high-risk adenocarcinoma of the distal esophagus and gastro-esophageal junction

   IMRT-SIB 3DCRT[15]
Type Outcome (n = 18) (n = 15)
SURVIVAL median followup 952 days 570 days (19 months)
median DFS not reached 690 days (23 months)
DFS (1 year) 88% 80%
DFS (2 years) 82% 44%
median OS 3 years (36 months) 1.8 years (21 months)
OS (1 year) 88% 65%
OS (2 years) 76% 38%
relapse: local 3 (17%) 0 (0%)
  relapse: distant 7 (39%) 6 (40%)
TOXICITY pulmonary toxicity (≤90 days) 4 (22%) 2 (15%)
esophageal toxicity (≤90 days) 9 (50%) 1 (7%)
pulmonary toxicity (>90 days) 5 (28%) 3 (20%)
  esophageal toxicity (>90 days) 1 (6%) 2 (13%)